Literature DB >> 32111452

Ocular conditions and dry eye due to traditional and new forms of smoking: A review.

Dimitra Makrynioti1, Zoi Zagoriti2, Constantinos Koutsojannis3, Philip B Morgan4, George Lagoumintzis5.   

Abstract

Addiction to cigarette smoking has high prevalence rates recorded worldwide. Smoking has been linked to several life-threatening systemic conditions such as cancer, heart attack and stroke, in addition to a range of ocular pathologies. In recent years, electronic cigarettes (EC) have emerged as alternatives to smoking. ECs are nicotine delivery devices which produce an aerosol by heating, rather than combusting, a liquid which contains nicotine, flavours and preservatives. This review focuses on the association of traditional and new forms of smoking with dry eye disease, contact lens wear and four other common ocular diseases: cataract, age-related macular degeneration, glaucoma and Graves' ophthalmopathy. It is concluded that smoking and vaping appear as a risk factor for the aforementioned ocular conditions. An evidence-based, clear link between cigarette smoking, or EC vaping and ocular problems is yet to be discovered.
Copyright © 2020 British Contact Lens Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Conventional cigarettes; Dry eye disease; Electronic cigarettes; Nicotine uptake; Smoking; Vaping

Mesh:

Year:  2020        PMID: 32111452     DOI: 10.1016/j.clae.2020.02.009

Source DB:  PubMed          Journal:  Cont Lens Anterior Eye        ISSN: 1367-0484            Impact factor:   3.077


  2 in total

1.  Smoking, urinary cotinine levels and incidence of visual impairment.

Authors:  So Young Han; Yoosoo Chang; Hocheol Shin; Chul Young Choi; Seungho Ryu
Journal:  Sci Rep       Date:  2021-01-11       Impact factor: 4.379

2.  Prevalence of dry eye disease among Chinese high school students during the COVID-19 outbreak.

Authors:  Feng Lin; Yuying Cai; Xinfeng Fei; Yimin Wang; Minwen Zhou; Yan Liu
Journal:  BMC Ophthalmol       Date:  2022-04-26       Impact factor: 2.086

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.